144 related articles for article (PubMed ID: 31815431)
1. The Brain Exposure Efficiency (BEE) Score.
Gupta M; Bogdanowicz T; Reed MA; Barden CJ; Weaver DF
ACS Chem Neurosci; 2020 Jan; 11(2):205-224. PubMed ID: 31815431
[TBL] [Abstract][Full Text] [Related]
2. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
[TBL] [Abstract][Full Text] [Related]
3. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
[TBL] [Abstract][Full Text] [Related]
4. Prediction of brain:blood unbound concentration ratios in CNS drug discovery employing in silico and in vitro model systems.
Liu H; Dong K; Zhang W; Summerfield SG; Terstappen GC
Drug Discov Today; 2018 Jul; 23(7):1357-1372. PubMed ID: 29548981
[TBL] [Abstract][Full Text] [Related]
5. Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates.
Braun C; Sakamoto A; Fuchs H; Ishiguro N; Suzuki S; Cui Y; Klinder K; Watanabe M; Terasaki T; Sauer A
Mol Pharm; 2017 Oct; 14(10):3436-3447. PubMed ID: 28880093
[TBL] [Abstract][Full Text] [Related]
6. A Practical Perspective on the Evaluation of Small Molecule CNS Penetration in Drug Discovery.
Huang L; Wells MC; Zhao Z
Drug Metab Lett; 2019; 13(2):78-94. PubMed ID: 30854983
[TBL] [Abstract][Full Text] [Related]
7. Translational CNS Steady-State Drug Disposition Model in Rats, Monkeys, and Humans for Quantitative Prediction of Brain-to-Plasma and Cerebrospinal Fluid-to-Plasma Unbound Concentration Ratios.
Sato S; Matsumiya K; Tohyama K; Kosugi Y
AAPS J; 2021 Jun; 23(4):81. PubMed ID: 34085128
[TBL] [Abstract][Full Text] [Related]
8. Experimental and Computational Methods to Assess Central Nervous System Penetration of Small Molecules.
Gupta M; Feng J; Bhisetti G
Molecules; 2024 Mar; 29(6):. PubMed ID: 38542901
[TBL] [Abstract][Full Text] [Related]
9. Examining the Uptake of Central Nervous System Drugs and Candidates across the Blood-Brain Barrier.
Summerfield SG; Zhang Y; Liu H
J Pharmacol Exp Ther; 2016 Aug; 358(2):294-305. PubMed ID: 27194478
[TBL] [Abstract][Full Text] [Related]
10. Successful Prediction of Human Steady-State Unbound Brain-to-Plasma Concentration Ratio of P-gp Substrates Using the Proteomics-Informed Relative Expression Factor Approach.
Storelli F; Anoshchenko O; Unadkat JD
Clin Pharmacol Ther; 2021 Aug; 110(2):432-442. PubMed ID: 33675056
[TBL] [Abstract][Full Text] [Related]
11. Role of breast cancer resistance protein (BCRP) as active efflux transporter on blood-brain barrier (BBB) permeability.
Garg P; Dhakne R; Belekar V
Mol Divers; 2015 Feb; 19(1):163-72. PubMed ID: 25502234
[TBL] [Abstract][Full Text] [Related]
12. Application of an in Vitro Blood-Brain Barrier Model in the Selection of Experimental Drug Candidates for the Treatment of Huntington's Disease.
Di Marco A; Gonzalez Paz O; Fini I; Vignone D; Cellucci A; Battista MR; Auciello G; Orsatti L; Zini M; Monteagudo E; Khetarpal V; Rose M; Dominguez C; Herbst T; Toledo-Sherman L; Summa V; Muñoz-Sanjuán I
Mol Pharm; 2019 May; 16(5):2069-2082. PubMed ID: 30916978
[TBL] [Abstract][Full Text] [Related]
13. Restricting CNS penetration of drugs to minimise adverse events: role of drug transporters.
Bagal S; Bungay P
Drug Discov Today Technol; 2014 Jun; 12():e79-85. PubMed ID: 25027378
[TBL] [Abstract][Full Text] [Related]
14. A Computational Physics-based Approach to Predict Unbound Brain-to-Plasma Partition Coefficient, K
Lawrenz M; Svensson M; Kato M; Dingley KH; Chief Elk J; Nie Z; Zou Y; Kaplan Z; Lagiakos HR; Igawa H; Therrien E
J Chem Inf Model; 2023 Jun; 63(12):3786-3798. PubMed ID: 37267072
[TBL] [Abstract][Full Text] [Related]
15. Muscle to Brain Partitioning as Measure of Transporter-Mediated Efflux at the Rat Blood-Brain Barrier and Its Implementation into Compound Optimization in Drug Discovery.
Cui Y; Lotz R; Rapp H; Klinder K; Himstedt A; Sauer A
Pharmaceutics; 2019 Nov; 11(11):. PubMed ID: 31718023
[TBL] [Abstract][Full Text] [Related]
16. Rate and extent of mitragynine and 7-hydroxymitragynine blood-brain barrier transport and their intra-brain distribution: the missing link in pharmacodynamic studies.
Yusof SR; Mohd Uzid M; Teh EH; Hanapi NA; Mohideen M; Mohamad Arshad AS; Mordi MN; Loryan I; Hammarlund-Udenaes M
Addict Biol; 2019 Sep; 24(5):935-945. PubMed ID: 30088322
[TBL] [Abstract][Full Text] [Related]
17. Unbound Brain-to-Plasma Partition Coefficient, K
Loryan I; Reichel A; Feng B; Bundgaard C; Shaffer C; Kalvass C; Bednarczyk D; Morrison D; Lesuisse D; Hoppe E; Terstappen GC; Fischer H; Di L; Colclough N; Summerfield S; Buckley ST; Maurer TS; Fridén M
Pharm Res; 2022 Jul; 39(7):1321-1341. PubMed ID: 35411506
[TBL] [Abstract][Full Text] [Related]
18. Current State and Future Perspectives in QSAR Models to Predict Blood- Brain Barrier Penetration in Central Nervous System Drug R&D.
Morales JF; Montoto SS; Fagiolino P; Ruiz ME
Mini Rev Med Chem; 2017; 17(3):247-257. PubMed ID: 27739359
[TBL] [Abstract][Full Text] [Related]
19. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
[TBL] [Abstract][Full Text] [Related]
20. Revisiting atenolol as a low passive permeability marker.
Chen X; Slättengren T; de Lange ECM; Smith DE; Hammarlund-Udenaes M
Fluids Barriers CNS; 2017 Oct; 14(1):30. PubMed ID: 29089037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
